Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Details)

v3.8.0.1
Quarterly Financial Information (unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 5,357,000 [1] $ 36,183,000 [1] $ 10,890,000 [1] $ 260,000 [1] $ 524,000 $ 635,000 $ 443,000 $ 3,962,000 $ 52,690,000 $ 5,564,000 $ 55,447,000
Restructuring (charge) credit 4,000 29,000 (1,460,000) (2,020,000) (4,551,000)   21,000 (36,000)      
Operating costs and expenses (7,371,000) (7,562,000) (8,119,000) (9,160,000) (13,432,000) (12,727,000) (18,482,000) (17,915,000) (35,659,000) (67,122,000) (95,171,000)
Income (loss) from operations (2,010,000) 28,650,000 1,311,000 (10,920,000) (17,459,000) (12,092,000) (18,018,000) (13,989,000) 17,031,000 (61,558,000) (39,724,000)
Other income (expense), net 648,000 (600,000) (1,026,000) 205,000 (21,000) [2] (433,000) [2] 2,858,000 [2] 5,624,000 [2]      
Income (loss) before income tax (1,362,000) 28,050,000 285,000 (10,715,000)         16,258,000 (53,530,000) (20,606,000)
Provision for income tax benefit (expense) 44,000 (1,706,000)             (1,662,000) 0 0
Net income (loss) and comprehensive income (loss) $ (1,318,000) $ 26,344,000 $ 285,000 $ (10,715,000) $ (17,480,000) $ (12,525,000) $ (15,160,000) $ (8,365,000) $ 14,596,000 $ (53,530,000) $ (20,606,000)
Basic net income (loss) per share of common stock $ (0.16) $ 2.06 $ 0.02 $ (2.37) $ (2.89) $ (2.08) $ (2.52) $ (1.40) $ 0.75 $ (8.89) $ (3.50)
Diluted net income (loss) per share of common stock $ (0.16) [3] $ 1.98 [3] $ 0.02 [3] $ (2.37) [3] $ (2.89) $ (2.08) $ (2.52) $ (1.40) $ 0.73 $ (8.89) $ (3.50)
[1] In the third quarter of 2017, total revenues include upfront and milestone payments relating to various out-licensing arrangements, including $35.4 million of license fee revenue recognized in connection with the license agreements with Novartis, and, in the second quarter of 2017, total revenues include a $10.0 million milestone earned under the license agreement with Novartis International.
[2] Fluctuations in 2016 primarily relate to (losses) gains on the revaluation of the contingent warrant liabilities.
[3] For the quarters ended June 30, 2017 and September 30, 2017, the Company’s diluted net income per share of common stock was computed by giving effect to all potentially dilutive common stock equivalents outstanding during each of these periods.